Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.31 |
| ▸ | HPN | P05981 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30946814 | 0.88 | ALOX5 (0.34) | PIK3CDALOX5EPHX1 | |
| SCHEMBL11682920 | 0.84 | ALOX5 (0.48) | ALOX5EPHX1 | |
| SCHEMBL17069437 | 0.84 | — | — | |
| SCHEMBL1225233 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL28162205 | 0.81 | — | — | |
| SCHEMBL2085370 | 0.80 | PIK3CD (0.39) | PIK3CDBCL2A1 | |
| SCHEMBL15483713 | 0.80 | PIK3CD (0.39) | PIK3CDBCL2A1 | |
| SCHEMBL9393481 | 0.80 | PIK3CD (0.39) | PIK3CDBCL2A1 | |
| SCHEMBL930716 | 0.79 | EPHX1 (0.56) | ALOX5EPHX1 | |
| SCHEMBL930588 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115087655-A | Benzimidazole derivatives | 辉瑞公司 | 2022-09-20 | — | — | CN | claimed |
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | claimed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | claimed |
| EP-2091947-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2009-08-26 | — | — | EP | claimed |
| EP-2001875-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2008079787-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| US-20240124439-A1 | Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease | PFIZER INC. (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4077316-A1 | BENZIMIDAZOLE DERIVATIVES | Pfizer Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087655-A | Benzimidazole derivatives | 辉瑞公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-110248939-B | Tyrosine amide derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20220062243-A1 | P14-Kinase Inhibitors with Anti-Cancer Activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| EP-2152671-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2010-02-17 | — | — | EP | disclosed |
| EP-2091947-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090105255-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | disclosed |
| EP-2001875-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008142454-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008079787-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062243-A1 | P14-Kinase Inhibitors with Anti-Cancer Activity | PI4KB, CDKN1A, PI4KA | PIK3CD 158/4885ALOX5 4212/4885EPHX1 3483/4885 |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | PIK3CD 3435/4885ALOX5 1155/4885EPHX1 1952/4885 |
| US-20090105255-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | PIK3CD 985/4885ALOX5 2230/4885EPHX1 4411/4885 |
| US-20240124439-A1 | Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease | ITK, PDXK, HRH4 | PIK3CD 145/4885ALOX5 1494/4885EPHX1 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.